Chemify

Market position

Chemify positions itself as a digital chemistry and small-molecule discovery and synthesis company aiming to be a "Chemputation Engine" for chemistry. The company reported partnerships with 6 of the 20 largest pharmaceutical companies as of 2025, has been named by Bloomberg among top UK startups to watch and listed by Sifted among drug discovery startups to watch, and operates in a field where AI discovery peers such as Lila Sciences have raised large financing rounds.

Chemify emphasizes that its designs are synthesis-aware and that route selection draws on reactions it has itself validated and automated on its own robotics, which it contrasts with retrosynthesis based on unreliable literature references and with AI outputs that propose molecules that cannot be made. The χDL language is presented as enabling standardized, hardware-agnostic and exactly reproducible synthesis procedures, and the company offers upfront algorithmic "Chemputability" scoring of makeability before synthesis begins.

Technology

The platform, Chemputation, spans four layers: Quantum Chemputation, a design process combining quantum mechanics with inverse design to generate synthesis-aware molecules; ASSEMBLER, route-optimization software that selects synthetic paths from a proprietary database of pre-validated, optimized and automated reaction classes; χDL, described by the company as the world's first universal, hardware-agnostic chemical programming language, in which routes are encoded with guardrails and error checks and can be encrypted for reproducibility and IP protection; and robotic automation that executes those workflows from reaction optimization through workup, purification and analysis. Reaction data such as reagents, catalysts, temperature, pressure and yield are captured in real time and fed back into machine-learning models to optimize pathways. The company says it supports over 100 reaction classes, maintains tens of thousands of validated automated reactions, and can repeatedly execute routes of 15 or more steps.

Go-to-market

Chemify sells through direct partnerships and collaborations with pharmaceutical, biotech and materials companies, supported by a business development function and a presence at industry conferences such as BIO International Convention, Drug Discovery Chemistry, AI in Drug Discovery and the EFMC International Symposium on Medicinal Chemistry. Press releases, published research and media coverage are also used to reach prospective partners.

Pharmaceutical, biotech and materials-science companies and academic scientists seeking novel small molecules, including partners in cardiometabolic disease, oncology and neurodegeneration, plus applications in catalysts and electronic materials.

Geography

Headquartered in Glasgow, Scotland, with the Advanced Research Centre site at 11 Chapel Lane and the Maryhill Chemifarm at Oakbank Industrial Estate. The company has announced plans for a Chemifarm facility in Silicon Valley and describes broader global expansion into a network of digital chemistry hubs.

History

Following its 2022 founding, Chemify announced $43 million in Series A funding in August 2023 and disclosed partnerships with Dewpoint Therapeutics (September 2023) and Prepaire Labs (January 2024). It hired Kevin McGowan as Chief Business Officer in August 2024 and received grant funding in October 2024 to design drug leads for tuberculosis and malaria, with an additional tuberculosis-focused grant in December 2025. In June 2025 it opened the first Chemifarm automated synthesis facility in Glasgow, and in October 2025 it raised more than $50 million in an oversubscribed Series B co-led by Wing Venture Capital and Insight Partners. In February 2026 Zeon Corporation made a strategic investment, and Chemify announced a collaboration with Sanacor on small-molecule cardiometabolic therapies; in April 2026 the company announced three published papers validating the Chemputation platform.

Risks & controversies

The company's approach depends on continued validation of automated synthesis at scale and on expanding capital-intensive Chemifarm facilities; the first Glasgow facility alone was reported to cost $16 million, and further global hubs are planned. It competes in a well-funded AI-for-discovery field where rivals have raised substantially larger rounds.